The expanded laboratory capacity supports growing demand for flexibility in process development, scale-up, and manufacturing for both non-high-potency and high-potency programs. The new suites total 627 sq ft and are equipped with walk-in fume hoods capable of supporting up to 100L glass reactors. The flexible design accommodates specialized equipment, including isolators, glove boxes, and lyophilizers, that can be brought in as needed depending on project requirements.
Eurofins laboratories are supported by a dedicated analytical laboratory and an adjacent GMP warehouse, creating an integrated setup spanning development, analytical support, material management, and manufacturing readiness.
The expansion adds capacity for handling increasingly complex and highly potent molecules across development stages. It also extends the site’s integrated antibody-drug conjugate (ADC) capabilities, enabling production of linkers and payloads for conjugation with monoclonal antibodies manufactured on-site, reducing the need to coordinate across multiple external suppliers.
The move reflects broader industry demand for capacity to support targeted therapies and next-generation medicines.
Source: chemanager-online.com
LEO Pharma has agreed to buy the worldwide rights to Tanabe Pharma’s drug in development for photosensitive genetic disorder treatment, bolstering the Danish company’s pipeline that has already undergone expansion this year.
Merck & Co. and Moderna announced encouraging results from a large clinical trial testing a new, personalized cancer treatment for melanoma, a serious form of skin cancer. The treatment, called intismeran, is made individually for each patient using their own tumor’s DNA. It’s designed to teach the immune system to recognize and attack cancer cells unique to that person.
Everything is bigger in Texas. And so it is with Bristol Myers Squibb’s $2.3 billion investment in a manufacturing campus in Houston, which comes in at more than twice the price the company estimated in a government application earlier this year.
